American Diabetes Association

Man wearing a cap mask while sleeping
#American Diabetes Association #Diabetes #Eli Lilly #GLP-1 #Phase III trial #Sleep apnoea #Weight loss

Weight loss drug reduces sleep apnoea severity by 62%

Tirzepatide demonstrated a mean reduction of up to 62.8% on the apnoea-hypopnea index (AHI) compared to placebo in the SURMOUNT-OSA Phase III clinical trials. The drug was tested for the treatment of moderate-to-severe obstructive sleep apnoea (OSA) in adults with obesity, with and without positive airway… Read More

#News #Trending News

#American Diabetes Association #Diabetes #Events #GLP-1 #Obesity #Weight loss

New evidence on GLP-1 receptor agonists at ADA 2024

Further insights on glucagon-like peptide-1 (GLP-1) receptor agonists were presented at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida, 21-24 June. Obesity affects 41.9% of adults and 19.7% of children and adolescents in the US, and 90% of people with diabetes also live… Read More

#News #Trending News